AMP-activated protein kinase (AMPK) serves as an energy-sensing protein kinase that is activated by a variety of metabolic stresses that lower cellular energy levels.
INTRODUCTION
The mammalian 5'AMP-activated protein kinase (AMPK) serves as an energysensing protein kinase. It is activated by a variety of metabolic stresses that lower cellular energy levels. These include exercise, nutrient starvation, ischemia/hypoxia, heat shock, and metabolic poisoning (1) (2) (3) (4) . AMPK is also activated by a number of pharmacological interventions. 5-aminoimidazole-4-carboxamide 1-b-D-ribonucleoside (AICAR), which is converted to an AMP analog upon entering the cells, is a commonly used tool for activating AMPK (5) . Leptin (6) , adiponectin (7) , metformin (8, 9) and rosiglitazone (8) activate AMPK through poorly characterized mechanisms that may not involve energy depletion. Activation of AMPK stimulates fatty acid oxidation, hexokinase activity, uptake of glucose into skeletal muscle, all of which generate reduced nucleoside cofactors and ATP, and represses hepatic gluconeogenic and fatty acid synthesis enzymes (10) , which consume these.
AMPK is a heterotrimeric complex consisting of a catalytic ( ) subunit and two regulatory subunits ( and ) (11) . Isoforms of all three subunits have been identified, including two isoforms of the catalytic subunit, 1 and 2 (9) , two of the regulatory subunit, β1 and β2 and three of the regulatory subunit, γ1, γ2, γ3 (12) . Formation of the trimeric complex is necessary for optimal kinase activity (11, 13) . Numerous studies have shown that changes in the cellular energy state activate AMPK through mechanisms involving an AMP allosteric regulation, and phosphorylation by an upstream kinase on threonine residue 172 within the catalytic subunit (14) . This kinase has been recently identified as LKB1 (15, 16) . Although activation of AMPK appears to be a direct consequence of an increase in the AMP:ATP ratio as a result of metabolic stresses that Regulation of AMPK activity by NAD and NADH deplete cellular ATP, Lopaschuk and others have shown that cardiac AMPK activity could be changed under conditions where significant alterations in the AMP/ATP ratio do not occur (17, 18) . Moreover, Frederich and Balschi demonstrated in isolated hearts that metabolic inhibitors activated AMPK to a greater extent than predicted by the measured level of AMP and ATP, and suggested other factors may activate AMPK in the heart (19) . Other studies in various tissues also suggest that AMPK can be activated by mechanisms that do not involve changes in adenine nucleotide levels (20, 6, 9) . Another sensor of the metabolic state of the cell is the NAD/NADH redox potential. Studies have shown that a high intracellular NADH/NAD ratio inhibits major metabolic pathways such as glycolysis and fatty acid oxidation (21) . In the present paper we provide evidence that NAD activates and NADH inhibits the activity of the recombinant AMPK heterotrimeric enzyme. This kind of metabolic regulation might provide important physiological benefit and an alternative explanation to the activation of AMPK in the absence of changes in adenine nucleotide levels.
.
Regulation of AMPK activity by NAD and NADH

EXPERIMENTAL PROCEDURE
Reagents -γ 33 P ATP was purchased from Perkin Elmer (Boston, MA). All other reagents were purchased from Sigma (St. Louis, MO)
Plasmid construction-Co-expression of all three AMPK subunits is required for AMPK enzymatic activity. The α2, β1 and γ1 subunits were amplified from human muscle cDNA by PCR using primers containing a consensus Kozak sequence for proper translation of gene of interest. The cDNAs were subcloned into the expression vector pPR1, which contains the replication origin (oriP), and a CMV promoter. To mimic a phosphorylation state, the catalytic subunit was mutated at threonine 172, the residue that is normally phosphorylated in response to AMP, to an aspartic acid (T172D). α2 T172D was generated using QuickChange Site Directed Mutagenesis Kit (Stratagene, La Jolla, CA). To facilitate downstream detection and purification, a C-terminal Flag epitope and His-tag were incorporated into the β  subunit. Kinetic Model -The model for the rate of peptide phosphorylation, P[t], by AMPK was derived as described by Segel (23) assuming a rapid equilibrium assumption to give rise to equation 1 where K A , K B , K C and K N are dissociation constants; n is the Hill coefficient and α, β, γ, and δ are cooperativity constants ( Figure 5 ). 
Expression of WT and T172D AMPK in 293E cells
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RESULTS AND DISCUSSION
The mammalian AMPK is a heterotrimer consisting of a catalytic α subunit and two regulatory β and γ subunits. To mimic a phosphorylation state, we mutated the catalytic subunit at threonine 172, the residue that is normally phosphorylated in response to AMP, to an aspartic acid (T172D). The wild type (WT) α2 or T172D-α2, β1 and γ1 To test whether the redox state might have an effect on AMPK activity we examined the effect of β-NAD and NADH on this enzyme. Both the recombinant T172D-AMPK and the WT-AMPK enzymes were activated by β-NAD in a dose-dependent manner ( Figure 1A ,B) whereas NADH inhibited its activity ( Figure 1C,D) . Since the signal for AMPK activity obtained in the kinase assay was more robust using the T172D-AMPK enzyme as compared to the WT-AMPK, we used the former enzyme for all further experiments. This activity was not due to contaminants in the purified recombinant AMPK since this experiment when performed with purified fraction from a (Figure 2A ). In contrast, we observed a lesser effect of AMP on the ability of NAD to activate AMPK and at 3µM AMP an actual decrease in activity was apparent ( Figure 2B ). We further explored the effect of NADH on AMPK by systematically varying ATP, peptide, AMP and NADH concentrations.
Since NADH is a nucleotide it seemed reasonable that NADH would bind in either the ATP or AMP binding pocket and be competitive with respect to one or the other. to AMP and ATP might activate or inhibit AMPK activity (9, 19, 20) . However, to the best of our knowledge our study shows for the first time clear evidence that NADH inhibits AMPK activity. This study also shows that β-NAD can activate AMPK, although at a lesser extent than AMP and that at higher concentrations might even inhibit the activity. It is tempting to speculate that during myocardial ischemia when AMPK is activated, NADH that is produced by the process of fatty acid oxidation serves as a negative regulator of AMPK activity in order to improve the post-ischemic functional recovery of the heart. Stimulation of substrate oxidation and NADH formation under conditions when NADH is already high and cannot be utilized to form ATP might be harmful. The ability of NADH to inhibit AMPK might prevent this detrimental effect.
Other studies showed that the intracellular lactate concentration and the lactate/pyruvate ratio increase substantially in contracting muscle (26) . An effect of augmented lactate production to increase the cytoplasmic NADH/NAD ratio and to alter AMPK inhibition by NADH becomes an even more interesting phenomenon in view of latest studies showing that glucose-stimulated insulin secretion requires inhibition of AMPK (27) . Matschinsky et al (28) have shown that stimulation of pancreatic islets with high glucose prompted elevation of NADH in the islets. Once again we could speculate that this would potentially lead to inhibition of AMPK, which will then enable insulin-secretion. Finally, as insulin was shown to increase NADH/NAD redox state (29) , the question rises of whether this could be the reason for the observed inhibition of AMPK activity by insulin in isolated rat hearts (30) . 
